Advertisement
Vaccinex, Inc. (VCNX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
As of 09:51AM EDT. Market open.
| Previous Close | 2.6000 |
| Open | 2.5700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.4310 - 2.5700 |
| 52 Week Range | 1.3900 - 15.9600 |
| Volume | |
| Avg. Volume | 100,851 |
| Market Cap | 6.562M |
| Beta (5Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Clinical Trials Arena
Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint
The positive topline results demonstrated no serious treatment emergent adverse events.
- GuruFocus.com
Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc
Point72 Asset Management, led by renowned investor Steven Cohen (Trades, Portfolio), has recently initiated a position in Vaccinex Inc (NASDAQ:VCNX), a biotechnology company focused on cancer and neurodegenerative disease treatment. On February 6, 2024, the firm acquired 1,631,648 shares of Vaccinex Inc, marking a new holding in its investment portfolio. The shares were purchased at a price of $0.5863 each, reflecting a significant move by the firm into the biotech sector.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.